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  EVIDENCE-BASED ANSWER 
Substituting bupropion, nefazodone, or mirtazapine is beneficial. (Grade of recommendation: B, randomized 
controlled trials [RCTs].) Augmentation therapy with amantadine, bupropion, and buspirone is no better than 
placebo. (Grade of recommendation: B, RCTs.) Augmentation therapy with multiple other agents may be 
beneficial. (Grade of recommendation: D, open-label nonrandomized studies, case series, and case reports.) 
SSRI “drug holidays” may also be effective (Table 1). (Grade of recommendation: D, open-label nonrandomized 
studies.) 
 
TABLE 
Summary of treatment options for SSRI-induced sexual dysfunction 
Strategy Drugs considered RCT data Other data 
Switch 
therapy 
Bupropion SR, bupropion, 
mirtazapine, nefazodone 
Nefazodone 
effective 
All agents effective in 
nonrandomized open-label 
trials 
Augmentation 
Buspirone, amantadine, 
bupropion, cyproheptadine, 
dextroamphetamine, 
granisetron, ginkgo biloba, 
methylphenidate, mirtazapine, 
nefazodone, pemoline, 
sildenafil, yohimbine 
Small, 
transient 
effect with 
high-dose 
buspirone. 
Other RCT with buspirone, 
amantadine, and bupropion 
showed no difference vs 
placebo. Most agents 
effective in nonrandomized 
open-label trials, case-
series, or case reports. 
Placebo effect unknown 
Drug holiday 
Fluoxetine, paroxetine, 
sertraline 
None 
available 
Improvement in 2 of 4 
weekends for sertraline and 
paroxetine only 
  EVIDENCE SUMMARY 
SSRI-related sexual dysfunction may be dose dependent and diminish with time, but these aspects have not 
been evaluated prospectively. Data suggest that bupropion, nefazodone, and mirtazapine have little to no effect 
on sexual functioning.1 Changing from SSRIs to one of these agents may alleviate SSRI-induced sexual 
dysfunction. In a randomized double-blind study, patients experiencing sexual dysfunction on sertraline 
improved when switched to nefazodone 400 mg daily.2 Additional open-label nonrandomized studies of all 3 
agents suggest improved sexual functioning in 60% to 85% of patients with little to no loss of antidepressant 
efficacy.1,3,6 The potential for placebo effects makes interpreting these open-label trials more difficult. 
Three augmentation therapies have been tested in double-blind placebo-controlled trials. In the first, buspirone 
augmentation resulted in a statistical improvement in sexual functioning at weeks 2 and 3 of therapy, but not at 
weeks 1 and 4 (mean dose 48.5 mg per day).7 In the second, adding buspirone 20 to 30 mg per day, 
amantadine 50 to 100 mg per day, or placebo resulted in equal improvement in women’s sexual function.8 
Finally, in a third trial, adding bupropion or placebo showed equal improvement in sexual function.9 Multiple 
other agents have been tested in open-label nonrandomized studies, case series, and case reports. Most 
showed a beneficial effect, but results must be interpreted with caution. One open-label nonrandomized study of 
weekend “drug holidays” showed no benefit for fluoxetine and inconsistent results for paroxetine and 
sertraline.10 
  RECOMMENDATIONS FROM OTHERS 
Tertiary literature sources recommend the strategies described above.11 
Clinical Commentary by Michael Fisher, MD, additional references, search strategy, and detailed evidence table 
at http://www.fpin.org. 
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